Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion

Cell Adhesion and Migration

Volumn 6, Issue 6, 2012, Pages 547-553

  Perrot Applanat, Martine ^a,b   Di Benedetto, Melanie ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast tumor; Tumor cells; VEGF; VEGF receptors; VEGF A

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; SEMAPHORIN 3A; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; AUTOCRINE EFFECT; BREAST CANCER; BREAST TUMOR; CANCER CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUMOR CELL;

EID: 84872065517     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.23332     Document Type: Review

References (74)

1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25; PMID:9034784; http://dx.doi.org/10.1210/er.18. 1.4.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195- 27.
3. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-54; PMID:1711045.
4. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992; 267:6093-8; PMID:1556117.
5. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4:1317-26; PMID:8167412.
6. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267:26031-7; PMID:1464614.
7. Plouët J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, et al. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272:13390-6; PMID:9148962; http://dx.doi.org/10.1074/jbc.272.20. 13390.
8. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169:681-91; PMID:15911882; http://dx.doi.org/10.1083/jcb.200409115.
9. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22; PMID:9872925.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603-669.
11. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39:469-78; PMID:17002866; http://dx.doi.org/10.5483/BMBRep.2006.39.5.469.
12. Kappas NC, Zeng G, Chappell JC, Kearney JB, Hazarika S, Kallianos KG, et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 2008; 181:847-58; PMID:18504303; http://dx.doi.org/10. 1083/jcb.200709114.
13. Hervé M-A, Buteau-Lozano H, Vassy R, Bieche I, Velasco G, Pla M, et al. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol 2008; 172:167-78; PMID:18079435; http://dx.doi.org/10.2353/ajpath.2008. 070181.
14. Ancelin M, Buteau-Lozano H, Meduri G, Osborne-Pellegrin M, Sordello S, Plouët J, et al. A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci U S A 2002; 99:6023-8; PMID:11972026; http://dx.doi.org/10.1073/pnas.082110999.
15. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002; 16:2684-98; PMID:12381667; http://dx.doi.org/10.1101/gad.242002.
16. Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, Greco O, et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008; 68:2301-11; PMID:18381437; http://dx.doi.org/10.1158/0008-5472.CAN-07- 2011.
17. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-45; PMID:9529250; http://dx.doi.org/10.1016/S0092-8674(00)81402-6.
18. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12:129-35; PMID:11306513.
19. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005; 8:197-204; PMID:16328160; http://dx.doi.org/10.1007/s10456-005-9010-0.
20. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61:5736-40; PMID:11479209.
21. Miralem T, Steinberg R, Price D, Avraham H. VEGF(165) requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells. Oncogene 2001; 20:5511-24; PMID:11571649; http://dx.doi.org/10.1038/sj.onc.1204753.
22. Yasuoka H, Kodama R, Tsujimoto M, Yoshidome K, Akamatsu H, Nakahara M, et al. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer 2009; 9:220; PMID:19580679; http://dx.doi.org/10.1186/1471-2407-9-220.
23. Schoeffner DJ, Matheny SL, Akahane T, Factor V, Berry A, Merlino G, et al. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 2005; 85:608-23; PMID:15765121; http://dx.doi.org/10.1038/labinvest.3700258.
24. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of VEGF by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 2002; 62:4977-84; PMID:12208749.
25. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 2008; 6:1630-8; PMID:18922978; http://dx.doi.org/10.1158/1541-7786.MCR-07-2172.
26. Barr MP, Bouchier-Hayes DJ, Harmey JJ. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol 2008; 32:41-8; PMID:18097541.
27. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85:273-8; PMID:11461089; http://dx.doi.org/10.1054/bjoc.2001.1876.
28. Mercurio AM, Lipscomb EA, Bachelder RE. Nonangiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 2005; 10:283-90; PMID:16924371; http://dx.doi.org/10.1007/s10911-006-9001-9.
29. Lee T-H, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007; 4:e186; PMID:17550303; http://dx.doi.org/10.1371/journal.pmed.0040186.
30. Vintonenko N, Pelaez-Garavito I, Buteau-Lozano H, Toullec A, Lidereau R, Perret GY, et al. Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adh Migr 2011; 5:332-43; PMID:21897119; http://dx.doi.org/10.4161/cam.5.4.17287.
31. Chung J, Yoon S, Datta K, Bachelder RE, Mercurio AM. Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells. Cancer Res 2004; 64:4711-6; PMID:15256436; http://dx.doi.org/10.1158/0008-5472.CAN-04-0347.
32. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006; 66:1526-35; PMID:16452209; http://dx.doi.org/10.1158/0008-5472.CAN-05-3071.
33. Hutchings H, Ortega N, Plouët J. Extracellular matrixbound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 2003; 17:1520-2; PMID:12709411.
34. Goel HL, Pursell B, Standley C, Fogarty K, Mercurio AM. Neuropilin-2 regulates a6b1 integrin in the formation of focal adhesions and signaling. J Cell Sci 2012; 125:497-506; PMID:22302985; http://dx.doi.org/10.1242/jcs.094433.
35. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 2003; 63:5230-3; PMID:14500350.
36. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002; 62:7203-6; PMID:12499259.
37. Abdelkarim M, Vintonenko N, Starzec A, Robles A, Aubert J, Martin ML, et al. Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype. PLoS One 2011; 6:e23334; PMID:21858074; http://dx.doi.org/10.1371/journal.pone.0023334.
38. Wanami LS, Chen HY, Peiró S, García de Herreros A, Bachelder RE. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp Cell Res 2008; 314:2448-53; PMID:18554584; http://dx.doi.org/10.1016/j.yexcr.2008.05.004.
39. Darrington E, Zhong M, Vo BH, Khan SA. Vascular endothelial growth factor A, secreted in response to transforming growth factor-b1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. Asian J Androl 2012; 14:745-51; PMID:22705563; http://dx.doi.org/10.1038/aja. 2011.197.
40. Xu W, Huang JJ, Cheung PC. Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One 2012; 7:e34406; PMID:22470568; http://dx.doi.org/10.1371/journal.pone.0034406.
41. Beck B, Driessens G, Goossens S, Youssef KK, Kuchnio A, Caauwe A, et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011; 478:399-403; PMID:22012397; http://dx.doi.org/10. 1038/nature10525.
42. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002; 85:357-68; PMID:11948691; http://dx.doi.org/10.1002/jcb.10140.
43. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropi-lin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J Biol Chem 2001; 276:25520-31; PMID:11333271; http://dx.doi.org/10.1074/jbc.M102315200.
44. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11:53-67; PMID:17222790; http://dx.doi.org/10. 1016/j.ccr.2006.10.018.
45. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006; 108:1243-50; PMID:16621967; http://dx.doi.org/10.1182/blood-2005-11-4447.
46. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008; 13:331-42; PMID:18394556; http://dx.doi.org/10.1016/j.ccr.2008.01.029.
47. Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006; 5:1099-107; PMID:16731741; http://dx.doi.org/10.1158/1535-7163.MCT-05-0538.
48. Rizzolio S, Tamagnone L. Multifaceted role of neuropilins in cancer. Curr Med Chem 2011; 18:3563-75; PMID:21756227; http://dx.doi.org/10.2174/ 092986711796642544.
49. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 2005; 93:233-41; PMID:15956974; http://dx.doi.org/10.1038/sj.bjc.6602663.
50. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell 1997; 90:753-62; PMID:9288754; http://dx.doi.org/10.1016/S0092-8674(00)80535-8.
51. Parker MW, Xu P, Li X, Vander Kooi CW. Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 2012; 287:11082-9; PMID:22318724; http://dx.doi.org/10.1074/jbc.M111. 331140.
52. Parker MW, Xu P, Guo HF, Vander Kooi CW. Mechanism of Selective VEGF-A Binding by Neuropilin-1 Reveals a Basis for Specific Ligand Inhibition. PLoS One 2012; 7:e49177; PMID:23145112; http://dx.doi.org/10.1371/journal.pone.0049177.
53. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8:632-45; PMID:18580951; http://dx.doi.org/10.1038/nrc2404.
54. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell 2012; 22:145-52; PMID:22897846; http://dx.doi.org/10.1016/j.ccr.2012.06.031.
55. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A 2004; 101:11432-7; PMID:15273288; http://dx.doi.org/10.1073/pnas.0403969101.
56. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL. Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 1998; 21:1079-92; PMID:9856463; http://dx.doi.org/10.1016/S0896-6273(00)80625-X.
57. Renzi MJ, Feiner L, Koppel AM, Raper JA. A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1. J Neurosci 1999; 19:7870-80; PMID:10479689.
58. Chen H, He Z, Bagri A, Tessier-Lavigne M. Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron 1998; 21:1283-90; PMID:9883722; http://dx.doi.org/10.1016/S0896-6273(00) 80648-0.
59. Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 1998; 21:1093-100; PMID:9856464; http://dx.doi.org/10.1016/S0896-6273(00) 80626-1.
60. Geretti E, Shimizu A, Kurschat P, Klagsbrun M. Site-directed mutagenesis in the B-neuropilin-2 domain selectively enhances its affinity to VEGF165, but not to semaphorin 3F. J Biol Chem 2007; 282:25698-707; PMID:17595163; http://dx.doi.org/10.1074/jbc.M702942200.
61. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 1999; 146:233-42; PMID:10402473.
62. Adams RH, Lohrum M, Klostermann A, Betz H, Püschel AW. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J 1997; 16:6077-86; PMID:9321387; http://dx.doi.org/10.1093/emboj/16.20.6077.
63. Parker MW, Hellman LM, Xu P, Fried MG, Vander Kooi CW. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 2010; 49:4068-75; PMID:20387901; http://dx.doi.org/10.1021/bi100327r.
64. Shimizu M, Murakami Y, Suto F, Fujisawa H. Determination of cell adhesion sites of neuropilin-1. J Cell Biol 2000; 148:1283-93; PMID:10725340; http://dx.doi.org/10.1083/jcb.148.6.1283.
65. Glinka Y, Stoilova S, Mohammed N, Prud'homme GJ. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011; 32:613-21; PMID:21186301; http://dx.doi.org/10.1093/carcin/bgq281.
66. Cai H, Reed RR. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 1999; 19:6519-27; PMID:10414980.
67. Gao Y, Li M, Chen W, Simons M. Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol 2000; 184:373-9; PMID:10911369; http://dx.doi.org/10.1002/1097-4652(200009)184:3〈373::AID- JCP12〉3.0.CO;2-I.
68. Wang L, Mukhopadhyay D, Xu X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB J 2006; 20:1513-5; PMID:16754745; http://dx.doi.org/10.1096/fj.05-5504fje.
69. Prahst C, Héroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. J Biol Chem 2008; 283:25110-4; PMID:18628209; http://dx.doi.org/ 10.1074/jbc.C800137200.
70. Valdembri D, Caswell PT, Anderson KI, Schwarz JP, König I, Astanina E, et al. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol 2009; 7:e25; PMID:19175293; http://dx.doi.org/10.1371/journal.pbio.1000025.
71. Wang L, Lau JS, Patra CR, Cao Y, Bhattacharya S, Dutta S, et al. RGS-GAIP-interacting protein controls breast cancer progression. Mol Cancer Res 2010; 8:1591-600; PMID:21047775; http://dx.doi.org/10.1158/1541-7786.MCR-10- 0209.
72. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8:210-21; PMID:21364524; http://dx.doi.org/10.1038/nrclinonc.2011.21.
73. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8:880-7; PMID:18923433; http://dx.doi.org/10. 1038/nrc2505.
74. Hilmi C, Guyot M, Pagès G. VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids 2012; 2012:162692-8; PMID:22013509; http://dx.doi.org/10.1155/2012/162692.